Smartphones can accurately assess neuromuscular diseases, using video and free apps that provide faster and easier way to detect diseases earlier.

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

(MENAFN- GlobeNewsWire - Nasdaq) The report "Catalyst Monitor Q4 2025" highlights upcoming market opportunities in biotech and pharma, focusing on key approvals and trials such as Cytokinetics's ...

Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q4 2025 Outlook" report has been added to ResearchAndMarkets.com's offering. This report compiles published, predictive intelligence ...

Q3 2025 Earnings Call Transcript October 29, 2025 GSK plc beats earnings expectations. Reported EPS is $1.48, expectations were $1.26. Operator: Ladies and gentlemen, a very warm welcome to the GSK Q3 ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. The GSK executives are ...

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447] Technology appraisal guidance 25 March 2026 Dersimelagon for treating erythropoietic protoporphyria and ...